{"id":"placebo-r-chop","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL89731","moleculeType":"Small molecule","molecularWeight":"159.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-CHOP is a combination regimen where rituximab (a chimeric anti-CD20 monoclonal antibody) targets CD20 on B-cell surfaces to induce cell death, while CHOP chemotherapy agents work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and mitotic arrest. The trial design uses placebo as a control arm to evaluate the efficacy and safety of R-CHOP in the studied indication.","oneSentence":"This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:28:22.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma (specific subtype not specified in available information)"}]},"trialDetails":[{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT03263026","phase":"PHASE3","title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2018-03-20","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":256},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT05234684","phase":"PHASE3","title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2022-11-02","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT01122472","phase":"PHASE3","title":"Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2009-04","conditions":"Lymphoma, Diffuse Large B-cell Lymphoma","enrollment":650},{"nctId":"NCT00486759","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-07-26","conditions":"B-cell Lymphoma","enrollment":787},{"nctId":"NCT00790036","phase":"PHASE3","title":"Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07-24","conditions":"Diffuse Large B-cell Lymphoma","enrollment":742},{"nctId":"NCT01044004","phase":"NA","title":"Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2010-03","conditions":"B-cell Lymphoma, Fatigue","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo + R-CHOP","genericName":"Placebo + R-CHOP","companyName":"Beijing InnoCare Pharma Tech Co., Ltd.","companyId":"beijing-innocare-pharma-tech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas. Used for B-cell non-Hodgkin lymphoma (specific subtype not specified in available information).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}